BeyondSpring Inc. Ordinary Shares (BYSI) Dividend History

Company News

• SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

  SEED Therapeutics received FDA designations for its lead oncology asset ST-01156, a molecular glue that degrades RBM39. The company also announced strategic transactions with its largest shareholder, BeyondSpring, to diversify its shareholder base.

  GlobeNewswire Inc.
• BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

  BeyondSpring announced the sale of a portion of its equity interest in SEED Therapeutics for $35.4 million. The proceeds will be used to advance the late-stage clinical trials of BeyondSpring's lead asset, Plinabulin, a first-in-class anti-cancer agent.

  GlobeNewswire Inc.
• BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

  BeyondSpring presented updated results from a phase 2 study evaluating a triple combination of pembrolizumab, plinabulin, and docetaxel in metastatic NSCLC patients who progressed on prior immune checkpoint inhibitors. The regimen showed promising efficacy with a disease control rate of 89.3% and median PFS of 8.6 months.

  GlobeNewswire Inc.

  Featured Companies: MRK
• BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

  BeyondSpring's plinabulin/docetaxel combination demonstrated significant improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone, with an 80% reduction in grade 4 neutropenia and improved patient quality of life.

  GlobeNewswire Inc.
• BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

  BeyondSpring, a clinical-stage biopharmaceutical company, will present data on its lead anti-cancer asset, Plinabulin, at the 2024 World Conference on Lung Cancer and ESMO Congress 2024. The presentations will focus on the final efficacy data of Plinabulin and docetaxel combination in EGFR wild-type 2L/3L non-small cell lung cancer, as well as safety and efficacy results from other studies.

  GlobeNewswire Inc.

  Featured Companies: MRK